MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
139.85
+0.48
+0.34%
Opening 12:46 04/01 EDT
OPEN
139.17
PREV CLOSE
139.37
HIGH
140.84
LOW
138.82
VOLUME
1.69M
TURNOVER
--
52 WEEK HIGH
156.40
52 WEEK LOW
90.95
MARKET CAP
173.58B
P/E (TTM)
20.62
1D
5D
1M
3M
1Y
5Y
1D
AI-linked stocks see surge in ownership breadth, led by Palantir and GE Vernova
Seeking Alpha · 13h ago
Gilead Sciences's Q1 2026 Earnings: What to Expect
Barchart · 14h ago
Analysts’ Top Healthcare Picks: Centene (CNC), Eli Lilly & Co (LLY)
TipRanks · 1d ago
Is Trump to blame for delayed drug launches in Europe
Seeking Alpha · 1d ago
Wall Street crowds into AI plays as ownership breadth jumps
Seeking Alpha · 1d ago
2 "Defensive" Dividends Growing Fast (Thanks to AI)
NASDAQ · 1d ago
Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
TipRanks · 1d ago
Galapagos, Gilead enter pact to collaborate on T cell engager therapies
TipRanks · 1d ago
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

Webull offers Gilead Sciences Inc stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.